Compare Dyadic International, Inc. with Similar Stocks
Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 6.91% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -9.68
2
The company has declared negative results in Mar'2025 after 2 consecutive positive quarters
3
Risky - Negative EBITDA
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 32 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.99
-281.83%
12.33
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.09%
0%
-13.09%
6 Months
-13.55%
0%
-13.55%
1 Year
-43.97%
0%
-43.97%
2 Years
-42.84%
0%
-42.84%
3 Years
-50.48%
0%
-50.48%
4 Years
-76.67%
0%
-76.67%
5 Years
-85.92%
0%
-85.92%
Dyadic International, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.07%
EBIT Growth (5y)
6.91%
EBIT to Interest (avg)
-9.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.30
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.70%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
41.92
EV to EBIT
-6.89
EV to EBITDA
-6.89
EV to Capital Employed
-28.69
EV to Sales
11.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-582.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 5 Schemes (3.19%)
Foreign Institutions
Held by 5 Foreign Institutions (0.07%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1.00
0.40
150.00%
Operating Profit (PBDIT) excl Other Income
-1.70
-2.00
15.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.80
-2.00
10.00%
Operating Profit Margin (Excl OI)
-1,772.10%
-5,070.00%
329.79%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 150.00% vs -50.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 10.00% vs -25.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3.50
2.90
20.69%
Operating Profit (PBDIT) excl Other Income
-5.90
-8.20
28.05%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.80
-6.80
14.71%
Operating Profit Margin (Excl OI)
-1,681.70%
-2,825.80%
114.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 20.69% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 14.71% vs 29.90% in Dec 2023
About Dyadic International, Inc. 
Dyadic International, Inc.
Pharmaceuticals & Biotechnology
Dyadic International, Inc. is a global biotechnology company. The Company is focused on developing and licensing the C1 platform for use in human and animal pharmaceutical applications across the world. The Company has developed a method for producing commercial quantities of enzymes and other proteins, which it uses to develop and produce some of its own industrial enzymes, as well as licensing this technology to third parties. This technology is based on the Myceliopthora thermophila fungus, which the Company named C1. The C1 technology is a fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.
Company Coordinates 
Company Details
140 Intracoastal Pointe Dr Ste 404 , JUPITER FL : 33477-5094
Registrar Details






